AlphAIAlphAI — Financial news for AI agents
investing.comSEP 232 min read$DFTX

Definium Therapeutics at TD Cowen summit: phase iii data lift dt120

Definium Therapeutics (DFTX) presented phase III data for DT120, showing statistically significant results in treating generalized anxiety disorder and major depressive disorder. The drug demonstrated placebo-adjusted improvements of 5.4, 5.1, and 8.1 points in respective studies, with rapid clearance. The company is preparing for pre-NDA talks with the FDA to discuss filing strategies. Response and remission rates were lower than phase II but still clinically meaningful.

Original reporting
investing.com
Published Sep 23, 2026, 2:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$DFTX
Bullish
high confidence
Mentioned
$DFTX
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DFTXBullishHigh
01

Why it matters

The data could accelerate FDA discussions and attract partnership interest, influencing the company's market cap.

02

Market read

First‑report of pivotal trial results; likely to move the stock and impact the broader psychedelic‑therapy sector.

03

What to watch

Regulatory filing strategy and distribution model (buy‑and‑bill vs white‑bagging) could affect rollout speed.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Definium Therapeutics is a clinical‑stage biotech focusing on psychedelic‑derived treatments for mental health disorders.

Company-level read

Ticker impact

$DFTXBullishHigh confidence
Context

Definium Therapeutics presented statistically significant phase III results for DT120 in GAD and MDD at the TD Cowen summit.

Expected impact

Potential upside of 15‑20% if FDA filing proceeds smoothly.

Evidence & confidence

Phase III success is rare and material for a biotech; investors typically price in FDA approval prospects.

Market effects

Sector

Strengthens the neuropsychiatric drug sector and may lift peers with similar pipelines.

Regional

Positive for US biotech listings; limited global effect.

Global

Highlights growing interest in psychedelic therapeutics worldwide.

Counterpoint

What could challenge this read

Phase III remission rates fell versus Phase II; skeptics may question commercial viability.

Key entities

  • Company
    Definium Therapeutics Inc.

    Biotech developer of DT120.

  • Conference
    TD Cowen

    Host of the Novel Mechanisms in Neuropsychiatry Summit.

Read at source← All news

Related articles

SEP 20
$DFTXMedAI 8/10

Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for its LSD-based anxiety drug, DT120. The trial showed a 5.1-point improvement over placebo, similar to its previous trial. Psychedelic stocks often move together, and Definium's success could impact the broader sector. Hedge fund holdings of DFTX have increased, indicating growing institutional confidence.

yahoo.com2 min
SEP 19
$DFTXHighAI 9/10

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics (DFTX) reported positive Phase III results for DT120 in treating anxiety, with 32% of patients showing significant improvement vs. 14% on placebo. The drug was well-tolerated, and the company plans to meet with the FDA in Q4, aiming for an NDA submission in early 2027. Definium has $1.1B in cash and is preparing for commercialization.

finance.yahoo.com2 min
SEP 19
$DFTXHighAI 9/10

Definium Therapeutics (DFTX) Posts Another Positive Phase 3, Is The Stock Still A Bargain?

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The stock has surged 184.53% year-to-date, with a fair value estimate of $71.65, suggesting a 46% undervaluation. The company faces risks due to its pre-revenue status and reliance on DT120's success, with key Phase 3 readouts expected in 2026.

simplywall.st3 min
SEP 17
$DFTXMed

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?

Definium Therapeutics (DFTX) and Compass Pathways (CMPS) are in focus due to a White House push to accelerate psychedelic therapy research. Both companies are developing late-stage psychedelic therapies for psychiatric conditions. DFTX has a 62% upside with a $36.67 price target, while CMPS has a 227% upside with a $21.75 target. Both companies welcomed the executive order and highlighted their ongoing clinical trials.

stocktwits.com2 min